Hep Par 1 antibody stain for of hepatocellular carcinoma: The differential diagnosis 676 tumors tested using tissue microarrays and conventional tissue sections

被引:140
作者
Fan, Z [1 ]
de Rijn, MV [1 ]
Montgomery, K [1 ]
Rouse, RV [1 ]
机构
[1] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA
关键词
hepatocellular carcinoma; immunohistochemistry; hepatocyte paraffin 1; microarray;
D O I
10.1097/01.MP.0000052103.13730.20
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
A well-characterized positive marker for hepatocellular differentiation would be a useful tool for the diagnosis of hepatocellular carcinoma (HCC). The recently commercially available Hep Par I antibody (clone OCH1E5.2.10) has been reported to be a sensitive marker for HCC in parafflin embedded sections. Of non-hepatocellular tumors, occasional carcinomas have been reported to stain, most frequently gastric adenocarcinomas. This study further evaluated the staining of this antibody on a large number of neoplasms using tissue microarray technology as well as conventional tissue sections. Six hundred seventy-six tumors, including 19 cases of HCC, were tested. Eighteen of 19 cases of HCC were positive, 3 showing <5% staining. Two cases negative on the array showed focal staining when whole tissue sections from the same tumors were used. 16 of 34 cases of gastric carcinomas gave positive reactions, 4 of these showed less than 5% staining. Staining of gastric carcinomas was not limited to signet ring-type carcinomas or to areas of hepatoid differentiation. Only 1 of 11 cases of cholangio-carcinoma showed focal staining. We also noted several other tumors to stain occasionally, including adrenal cortical carcinoma (3/13), yolk sac tumor (2/9), colonic adenocarcinoma (8/106), lung carcinoma (3/52), ovarian carcinoma (5/48), and endocervical. adenocarcinoma (1/5). We did not observe staining in pancreatic carcinoma (11), renal cell carcinoma (36), breast carcinoma (85), melanoma (25), or mesothelioma (5). This study supports Hep Par I as a useful marker in the differential diagnosis of HCC, but with significant limitations. Cautious use of this antibody in a panel with other positive (alpha fetoprotein, CD10, poly-clonal carcinoembryonic antigen) and negative (epithelial. membrane antigen, monoclonal carcinoembryonic antigen, CD15) markers of hepatocellular differentiation may aid in the accurate diagnosis of HCC.
引用
收藏
页码:137 / 144
页数:8
相关论文
共 18 条
[11]  
Leong ASY, 1998, HISTOPATHOLOGY, V33, P318
[12]  
Maitra A, 2001, AM J CLIN PATHOL, V115, P689
[13]  
MIVERVINI MI, 1997, MODERN PATHOL, V10, P686
[14]   Clear cell carcinoma of the liver: A comparative immunohistochemical study with renal clear cell carcinoma [J].
Murakata, LA ;
Ishak, KG ;
Nzeako, UC .
MODERN PATHOLOGY, 2000, 13 (08) :874-881
[15]   Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry [J].
Natkunam, Y ;
Warnke, RA ;
Montgomery, K ;
Falini, B ;
van de Rijn, M .
MODERN PATHOLOGY, 2001, 14 (07) :686-694
[16]   Endogenous avidin-binding activity in paraffin-embedded tissue revealed after microwave treatment [J].
RodriguezSoto, J ;
Warnke, RA ;
Rouse, RV .
APPLIED IMMUNOHISTOCHEMISTRY, 1997, 5 (01) :59-62
[17]  
THUNG SN, 1979, LAB INVEST, V41, P101
[18]  
WENNERBERG AE, 1993, AM J PATHOL, V143, P1050